# High-dose Cephalexin for Cellulitis (HI-DOCC)

> **NCT05852262** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Ottawa Hospital Research Institute** · enrollment: 446 (estimated)

## Conditions studied

- Cellulitis

## Interventions

- **DRUG:** Cephalexin
- **DRUG:** Cephalexin

## Key facts

- **NCT ID:** NCT05852262
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-08-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-08-01
- **Target enrollment:** 446 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05852262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05852262, "High-dose Cephalexin for Cellulitis (HI-DOCC)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05852262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*